"Dr. Bach and others say the pharmaceutical industry is using this approach to justify major changes in federal regulations [...] The industry says the changes are needed to allow more flexibility in the type of deals they offer."
The New York Times and ProPublica 07/12/2017
Is Outcomes-Based Contracting Worth It?
Katie Thomas and Charles Ornstein examine the costs and benefits of outcomes-based contracting.
Following an op-ed by Anna Kaltenboeck and Dr. Peter Bach in Morning Consult, the New York Times and ProPublica take a closer look at the potential costs and benefits of outcomes-based contracting.
Read the full article here.